Table 1.
Association between TP53 rs1042522 C>G polymorphism and glioma risk.
| Genotype | Cases (N = 171) | Controls (N = 228) | P a | Crude OR (95% CI) | P | Adjusted OR (95% CI)b | P b |
|---|---|---|---|---|---|---|---|
| rs1042522 (HWE = 0.613) | |||||||
| CC | 54 (31.58) | 65 (28.51) | 1.00 | 1.00 | |||
| CG | 80 (46.78) | 117 (51.32) | 0.82 (0.52-1.30) | 0.406 | 0.83 (0.52-1.32) | 0.433 | |
| GG | 37 (21.64) | 46 (20.18) | 0.97 (0.55-1.70) | 0.911 | 1.01 (0.57-1.78) | 0.981 | |
| Additive | 0.822 | 0.97 (0.73-1.28) | 0.822 | 0.99 (0.74-1.31) | 0.922 | ||
| Dominant | 117 (68.42) | 163 (71.49) | 0.507 | 0.86 (0.56-1.33) | 0.507 | 0.88 (0.57-1.36) | 0.564 |
| Recessive | 134 (78.36) | 182 (79.82) | 0.722 | 1.09 (0.67-1.78) | 0.721 | 1.13 (0.69-1.85) | 0.630 |
OR: odds ratio; CI: confidence interval; HWE: Hardy-Weinberg equilibrium. aχ2 test for genotype distributions between glioma patients and cancer-free controls. bAdjusted for age and gender.